Cooperative Breast Cancer Tissue Resource (CBCTR)

具体目标 合作乳腺癌组织资源(CBCTR)是从1993年开始开发的，以应对 国家癌症研究所和美国四个地点之间的合作协议，以提供 乳腺癌组织向生物医学研究界用于肿瘤临床标志物的研究 预后和基于这些标记物的有前景的诊断试验的评估。当前应用程序 是对CBCTR申请再竞争三年的信函请求的回应 资金的问题。 具体地说，这四个机构将单独和共同 1.继续从CBCTR档案中向社区研究人员提供标本。 所提供的材料将主要以结合样本的组织微阵列的形式 从一张或两张幻灯片上的数百个案例中。然而，CBCTR将保留填补 当一些个别病例要求提供乳腺癌切片材料时， 只能用这种材料做实验。 2.继续收集和更新每个站点病例的临床和结果数据，以确保 为每个案例提供最准确和最新的材料。这样的审查将利用自动化来源 但也可能需要审查相当数量的主要来源：医疗 这些女性的记录。 3.对已被科研人员使用的病例补充CBCTR。CBCTR目前是一个 资源有限，没有通过增加新病例来补充。它的设计初衷是 被其客户的癌症研究人员使用，并不可避免地被耗尽。另一方面，如果资金 变得可用，国家癌症研究所决定维持一个大型和有代表性的 CBCTR中乳腺癌的混合，每个站点都可以通过积累新的资源来补充资源 自1993年以来被诊断的病例，当时最初的申请得到了资助，之后几乎没有新的 累积病例数。

Specific Aims The Cooperative Breast Cancer Tissue Resource (CBCTR) was developed, starting in 1993, in response to a cooperative agreement between the National Cancer Institute and four sites in the United States to provide breast cancer tissue to the biomedical research community for the study of clinical markers of tumor prognosis and the evaluation of promising diagnostic tests based on these markers. The current application is a response to a Letter Request for Applications for Recompetition of the CBCTR for a further three years of funding. Specifically, these four institutions individually and together will 1. Continue the provision of specimens to researchers in the community from the files of the CBCTR. The material provided will be mainly in the form of Tissue Microarrays that incorporate specimens from hundreds of cases on one or two slides. The CBCTR will, however, retain the ability to fill requests for sections of breast cancer material from a number of individual cases when the particular experiment can only be done with such material. 2. Continue the collection and updating of clinical and outcome data on each site's cases to assure the most accurate and contemporary material for each case. Such review will exploit automated sources of data but will also likely require review of a considerable number of primary sources: the medical records of these women. 3. Replenish the CBCTR for the cases that have been used by researchers. The CBCTR is currently a finite resource and is not being replenished with the addition of new cases. It has been designed to be used and, inevitably, depleted by its client cancer researchers. On the other hand, if funding becomes available and the National Cancer Institute decides to maintain a large and representative mixture of breast cancers in the CBCTR, each site can replenish the Resource by accrual of new cases diagnosed since 1993, when the original application was funded and after which few new cases were accrued.